Ingersoll Rand Reports 30% Net Income Decline in 2025 Driven by $400M Impairments, Continues Strategic Acquisitions & Share Buybacks

summarizeSummary

Ingersoll Rand reported a 30% drop in 2025 net income, largely due to over $400 million in impairment charges, while continuing strategic acquisitions and a substantial $1 billion share repurchase program.

check_boxKey Events

• Significant Net Income Decline

  Net income attributable to Ingersoll Rand Inc. decreased by 30% to $581.4 million in 2025 from $838.6 million in 2024, primarily driven by substantial impairment charges.

• Material Impairment Charges

  The company recognized $229.7 million in goodwill impairment, $43.7 million in other intangible asset impairment, and a $127.1 million loss on an equity method investment in 2025, totaling $400.5 million in non-cash charges. These impairments were mainly in the Precision and Science Technologies segment (Biopharma and Aerospace & Defense).

• Substantial Share Repurchase Program

  Ingersoll Rand repurchased $1,018.0 million of its common stock in 2025, a significant increase from $260.7 million in 2024, demonstrating a strong commitment to returning capital to shareholders, with the stock trading near its 52-week high.

• Revenue Growth Driven by Acquisitions

  Revenues increased by 5.7% to $7,650.9 million in 2025, primarily due to $419.9 million from acquisitions and favorable foreign currency impacts, partially offset by a decline in organic revenues.

auto_awesomeAnalysis

Ingersoll Rand's 2025 annual report reveals a significant 30% decline in net income, primarily due to substantial impairment charges totaling over $400 million related to goodwill, other intangible assets, and an equity method investment. This indicates challenges and a re-evaluation of value within certain segments, particularly Biopharma and Aerospace & Defense. Despite this profitability setback and a decline in organic revenues, the company demonstrated active portfolio management through strategic acquisitions and a robust capital allocation strategy, executing over $1 billion in share repurchases. Investors should monitor the performance of the impacted segments and the effectiveness of ongoing strategic initiatives to offset these impairments and drive organic growth.